共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
3.
4.
Evaluating the Protective Effects and Mechanisms of Diallyl Disulfide on Interlukin‐1β‐Induced Oxidative Stress and Mitochondrial Apoptotic Signaling Pathways in Cultured Chondrocytes 下载免费PDF全文
Azam Hosseinzadeh Davood Jafari Tunku Kamarul Abolfazll Bagheri Ali M. Sharifi 《Journal of cellular biochemistry》2017,118(7):1879-1888
5.
Suppression of RAD21 Induces Senescence of MDA‐MB‐231 Human Breast Cancer Cells Through RB1 Pathway Activation Via c‐Myc Downregulation 下载免费PDF全文
Shan Zhu Li Zhao Yueyang Li Pingfu Hou Ruosi Yao Jiang Tan Dongxu Liu Liping Han Baiqu Huang Jun Lu Yu Zhang 《Journal of cellular biochemistry》2016,117(6):1359-1369
6.
7.
Oxidative Stress Promotes Doxorubicin‐Induced Pgp and BCRP Expression in Colon Cancer Cells Under Hypoxic Conditions 下载免费PDF全文
Martha L. Pinzón‐Daza Yenith Cuellar‐Saenz Francisco Nualart Alejandro Ondo‐Mendez Lilia Del Riesgo Fabio Castillo‐Rivera Ruth Garzón 《Journal of cellular biochemistry》2017,118(7):1868-1878
8.
9.
10.
11.
12.
13.
Tomentosin Induces Telomere Shortening and Caspase‐Dependant Apoptosis in Cervical Cancer Cells 下载免费PDF全文
Nawel Merghoub Hassan El Btaouri Laila Benbacer Saïd Gmouh Chantal Trentesaux Bertrand Brassart Mohammed Attaleb Claudie Madoulet Thomas Wenner Saaid Amzazi Hamid Morjani Mohamed El Mzibri 《Journal of cellular biochemistry》2017,118(7):1689-1698
14.
Kenan Izgi Banu Iskender Johann Jauch Sedat Sezen Mustafa Cakir Maël Charpentier Halit Canatan Cagri Sakalar 《Journal of biochemical and molecular toxicology》2015,29(9):432-439
Myrtucommulone‐A is the active compound derived from Myrtus communis. The molecular targets of myrtucommulone‐A is widely unknown, which impedes its potential therapeutic use. In this study, we demonstrated the cytotoxicity of MC‐A and its potential to induce apoptosis in cancer cells. Myrtucommulone‐A was also found to be antiproliferative and strongly inhibited cancer cell migration. Eighty four apoptotic pathway genes were used to assess the effect of myrtucommulone‐A on cancer cells. Myrtucommulone‐A mediated an increase in apoptotic genes including Fas, FasL, Gadd45a, Tnf, Tnfsf12, Trp53, and caspase 4. The increase in myrtucommulone‐A dose (25 μM versus 6.25 μM) also upregulated the expression of genes, which are involved mainly in apoptosis, regulation of apoptosis, role of mitochondria in apoptotic signaling, cytokine activity, and tumor necrosis factor signaling. Our data indicate that myrtucommulone‐A could be utilized as a potential therapeutic compound with its molecular targets in apoptotic pathways. 相似文献
15.
16.
Nimbolide inhibits IGF‐I‐mediated PI3K/Akt and MAPK signalling in human breast cancer cell lines (MCF‐7 and MDA‐MB‐231) 下载免费PDF全文
Perumal Elumalai Ramachandran Arunkumar Chellakkan Selvanesan Benson Govindaraj Sharmila Jagadeesan Arunakaran 《Cell biochemistry and function》2014,32(5):476-484
The insulin‐like growth factor I (IGF‐I) signalling pathway contributes a major role on various cancer cell proliferation, survival and cell cycle. The present study was aimed to investigate the effect of nimbolide on IGF signalling and cell cycle arrest in MCF‐7 and MDA‐MB‐231 breast cancer cell lines. The protein expression of IGF signalling molecules and cell cycle protein levels was assessed by western blot analysis. In order to study the interaction of nimbolide on IGF‐1 signalling pathway, IGF‐I and phosphoinositide 3‐kinase (PI3K) inhibitor (LY294002) were used to treat MCF‐7 and MDA‐MB‐231 cells. Further, the cell cycle arrest was analysed by flow cytometry. The protein expression of IGF signalling molecules was significantly decreased in nimbolide‐treated breast cancer cells. PI3K inhibitor and IGF‐I with nimbolide treatment notably inhibited phosphorylated Akt. The cell cycle arrest was observed at the G0/G1 phase, and accumulation of apoptotic cells was observed in nimbolide‐treated breast cancer cell lines. Nimbolide also increased the protein expression of p21 and decreased the cyclins in both the cell lines. Nimbolide decreases the proliferation of breast cancer cells by modulating the IGF signalling molecules, which could be very useful for the breast cancer treatment. Copyright © 2014 John Wiley & Sons, Ltd. 相似文献
17.
18.
Low‐Dose Farnesyltransferase Inhibitor Suppresses HIF‐1α and Snail Expression in Triple‐Negative Breast Cancer MDA‐MB‐231 Cells In Vitro 下载免费PDF全文
Tomokazu Tanaka Yuichi Ikegami Harumasa Nakazawa Naohide Kuriyama Miwa Oki Jun‐ichi Hanai Vikas P. Sukhatme Masao Kaneki 《Journal of cellular physiology》2017,232(1):192-201
19.
The phosphoinositide 3-kinase (PI3K) signaling pathway plays an important role in processes critical for breast cancer progression and its upregulation confers increased resistance of cancer cells to chemotherapy and radiation. The present study aimed at determining the activity of ramentaceone, a constituent of species in the plant genera Drosera, toward breast cancer cells and defining the involvement of PI3K/Akt inhibition in ramentaceone-mediated cell death induction. The results showed that ramentaceone exhibited high antiproliferative activity toward breast cancer cells, in particular HER2-overexpressing breast cancer cells. The mode of cell death induced by ramentaceone was through apoptosis as determined by cytometric analysis of caspase activity and Annexin V staining. Apoptosis induction was found to be mediated by inhibition of PI3K/Akt signaling and through targeting its downstream anti-apoptotic effectors. Ramentaceone inhibited PI3-kinase activity, reduced the expression of the PI3K protein and inhibited the phosphorylation of the Akt protein in breast cancer cells. The expression of the anti-apoptotic Bcl-2 protein was decreased and the levels of the pro-apoptotic proteins, Bax and Bak, were elevated. Moreover, inhibition of PI3K and silencing of Akt expression increased the sensitivity of cells to ramentaceone-induced apoptosis. In conclusion, our results indicate that ramentaceone induces apoptosis in breast cancer cells through PI3K/Akt signaling inhibition. These findings suggest further investigation of ramentaceone as a potential therapeutic agent in breast cancer therapy, in particular HER2-positive breast cancer. 相似文献